New therapeutic targets in vascular biology^[*]

 

^* Highlights from the 2nd International Workshop

• References

• 1 Nisato RE, Tille J-C, Pepper MS. Lymphangiogenesis and tumor metastasis. Thromb Haemost 2003; 90: 591-7.
• 2 Czarny M, Liu J, Oh P, Schnitzer JE. Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide. J Biol Chem 2003; 278: 4424-30.
• 3 Dormond O, Rüegg C. Regulation of endothelial cell integrin function and angiogenesis by CO-2, cAMP and Protein Kinase A. Thromb Haemost 2003; 90: 577-85.
• 4 Cabrita MA, Christofori G. Sprouty Proteins: antagonists of endothelial cell signaling and more. Thromb Haemost 2003; 90: 586-90.
• 5 Gamble JR, Matthias LJ, Meyer G. et al. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 1993; 121: 931-43.
• 6 Lampugnani GM, Zanetti A, Corada M. et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phospha DEP-1/CD148. J Cell Biol 2003; 161: 793-804.
• 7 Schenkel AR, Mamdouh Z, Chen X. et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3: 143-50.
• 8 Mamdouh Z, Chen X, Pierini LM. et al. Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 2003; 421: 703-5.
• 9 Yadav Y, Larbi KY, Young RE. et al. Migration of leukocytes through the vessel wall and beyond. Thromb Haemost 2003; 90: 598-606.
• 10 Ancuta P, Rao R, Moses A. et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-7.
• 11 Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 2003; 83: 309-36.
• 12 Nishikawa SI, Hirashima M, Nishikawa S. et al. Cell biology of vascular endothelial cells. Ann NY Acad Sci 2001; 947: 35-40.
• 13 Fuller T, Korff T, Kilian A. et al. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 2003; 116: 2461-70.
• 14 Sampaolesi M, Torrente Y, Innocenzi A. et al. Cell therapy of alpha-sarcoglycan null dys-trophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301: 487-92.
• 15 Heissig B, Werb Z, Rafii S. et al. Role of c-kit/kit ligand signaling in regulating vasculogenesis. Thromb Haemost 2003; 90: 570-6.
• 16 Vajkoczy P, Blum S, Lamparter M. et al. Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogenesis. J Exp Med 2003; 197: 1755-65.
• 17 Parsonage G, Falciani F, Burman A. et al. Global gene expression profiles in fibroblasts from synovial, skin and lymphoid tissue reveals distinct cytokine and chemokine expression patterns. Thromb Haemost 2003; 90: 688-97.
• 18 Mach F. Statins as novel immunomodulators: From cell to potential clinical benefit. Thromb Haemost 2003; 90: 607-10.
• 19 Don AS, Kisker O, Dilda P. et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003; 3: 497-509.